Clinical Trials · NCT05936151
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 146
- Start date
- Jul 2023
- Locations
- 42 sites, 5 countries
- Primary endpoint
- Change from Baseline in Glomerular Filtration Rate (mGFR)